The only way to have missed hearing about this study would be to have no contact with the media in the last 24 hours. Right now, Matt Lauer is in the other room waxing eloquent and it was the top story on my news and medical alerts this morning. Last night, the experts on the […]
Some more statistical fluff. I don’t know the story of how the meta-analyses [study of studies] came to be and how the methodology was developed, but I know about it from the Cochrane Collaborations. Wherever and however aside, it’s pretty spectacular from where I sit. Both the metrics used and the way they’re displayed has […]
This is just some fluff. After all this time looking at the industry-funded clinical trials [RCTs], I’ve learned a few tricks for spotting the mechanics of deceit being used, but I realize that I need to say a bit about the basic science of RCTs before attempting to catalog things to look for. Data Transparency […]
Some of the more important learning in medicine doesn’t come from medical school, or residency, or even sitting at the feet of the masters. It comes from reflecting on the long days seeing patients – what kind of things keep coming up over and over? Early on, it hadn’t occurred to me that my own […]
I so rarely disagree with anything Ed Silverman of Pharmalot has to say, I relish the opportunity to disagree with him for a change. When I read that the AMA had voted to call for a ban on Direct-to-Consumer [DTC] ads on TV [doctor power…], I felt almost giddy about my fellow physicians finally making […]
In the last post [creative funding III & some other things…], I mentioned a 2009 Meta-analysis of antidepressant augmentation using Atypical Antipsychotics and I wanted to say some more about it: Atypical Antipsychotic Augmentation in Major Depressive Disorder: A Meta-Analysis of Placebo-Controlled Randomized Trials by J. Craig Nelson, M.D. and George I. Papakostas, M.D. American […]
I know creative funding I… and creative funding II… were probably as tedious to read as they were to write, but since they were not available on-line, I felt like I had to say what they were in order to talk about them. I’ve sort of slacked off of vetting Clinical Trials for a while. […]
Extended-Release Guanfacine for Hyperactivity in Children With Autism Spectrum Disorder by Lawrence Scahill, M.S.N., Ph.D., James T. McCracken, M.D., Bryan H. King, M.D., Carol Rockhill, M.D., Bhavik Shah, M.D., Laura Politte, M.D., Roy Sanders, M.D., Mendy Minjarez, Ph.D., Jennifer Cowen, Ph.D., Jennifer Mullett, R.N., Chris Page, B.S., Denise Ward, M.A., Yanhong Deng, M.P.H., Sandra Loo, […]
Back then, I was just four days old, so of course I didn’t understand. But now aged 74 years? I still don’t – either the then version or the now version…
Pfizer’s Geodon® [Ziprasidone] was the fifth Atypical Anipsychotic approved [2001]. The Orange Book lists its patent exclusivity through 2019, though it appears that generics have been approved since 2012 that are now available [see current costs] [I’ve given up trying parse patent/exclusivity information, so that’s all I know]. Independent of that confusion, there’s a Clinical […]